Vinorelbine and Intermittent Cyclophosphamide Sensitize an Aggressive Myc-Driven B-Cell Lymphoma to Anti-PD-1 by an Immunological Memory Effective Against Tumor Re-Challenge

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Apr 13

PMID 37048617

Authors

Stefania Orecchioni

Paolo Falvo

Giovanna Talarico

Giulia Mitola

Giulia Bravetti

Patrizia Mancuso

Paola Nicoli

Francesco Bertolini

Affiliations

Soon will be listed here.

Abstract

We have previously shown in triple-negative breast cancer (TNBC) models that a triple therapy (TT) including intermittent cyclophosphamide (C), vinorelbine (V), and anti-PD-1 activates antigen-presenting cells (APC) and generates stem like-T cells able to control local and metastatic tumor progression. In the present manuscript, we report the generation of a highly aggressive, anti-PD-1 resistant model of a high-grade, Myc-driven B-cell non-Hodgkin's lymphoma (NHL) that can be controlled in vivo by TT but not by other chemotherapeutic agents, including cytarabine (AraC), platinum (P), and doxorubicin (D). The immunological memory elicited in tumor-bearing mice by TT (but not by other treatments) can effectively control NHL re-challenge even at very high inoculum doses. TT re-shaped the landscape of circulating innate NK cells and adaptive immune cells, including B and T cells, and significantly reduced exhausted CD4 and CD8 TIM3PD-1 T cells in the spleens of treated mice.

Citing Articles

Age-dependent differences in breast tumor microenvironment: challenges and opportunities for efficacy studies in preclinical models.

Falvo P, Gruener S, Orecchioni S, Pisati F, Talarico G, Mitola G Cell Death Differ. 2025; .

PMID: 39870804 DOI: 10.1038/s41418-025-01447-1.

References

Beaver J, Pazdur R . The Wild West of Checkpoint Inhibitor Development. N Engl J Med. 2021; 386(14):1297-1301. DOI: 10.1056/NEJMp2116863. View

Ye X, Wang L, Nie M, Wang Y, Dong S, Ren W . A single-cell atlas of diffuse large B cell lymphoma. Cell Rep. 2022; 39(3):110713. DOI: 10.1016/j.celrep.2022.110713. View

Tilsed C, Principe N, Kidman J, Chin W, Orozco Morales M, Zemek R . CD4 T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy. Cell Rep. 2022; 41(13):111874. DOI: 10.1016/j.celrep.2022.111874. View

Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F . Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer. 2018; 118(10):1329-1336. PMC: 5959935. DOI: 10.1038/s41416-018-0076-z. View

Davoodi-Moghaddam Z, Jafari-Raddani F, Noori M, Bashash D . A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?. Transl Oncol. 2023; 30:101636. PMC: 9941575. DOI: 10.1016/j.tranon.2023.101636. View

Tanaka H, Matsushima H, Mizumoto N, Takashima A . Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res. 2009; 69(17):6978-86. PMC: 2769260. DOI: 10.1158/0008-5472.CAN-09-1101. View

Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F . Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016; 44(2):343-54. PMC: 4758865. DOI: 10.1016/j.immuni.2015.11.024. View

Falvo P, Orecchioni S, Hillje R, Raveane A, Mancuso P, Camisaschi C . Cyclophosphamide and Vinorelbine Activate Stem-Like CD8 T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer Res. 2020; 81(3):685-697. DOI: 10.1158/0008-5472.CAN-20-1818. View

Falvo P, Orecchioni S, Raveane A, Mitola G, Bertolini F . A "two-hit" (chemo)therapy to improve checkpoint inhibition in cancer. Oncoscience. 2021; 8:55-57. PMC: 8115984. DOI: 10.18632/oncoscience.533. View

10.

Visan I . TCF-1 progenitors. Nat Immunol. 2022; 23(7):988. DOI: 10.1038/s41590-022-01259-2. View

11.

Zsiros E, Lynam S, Attwood K, Wang C, Chilakapati S, Gomez E . Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020; 7(1):78-85. PMC: 7677872. DOI: 10.1001/jamaoncol.2020.5945. View

12.

Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801. PMC: 7393098. DOI: 10.1038/s41467-020-17670-y. View

13.

Bertolini F, Sukhatme V, Bouche G . Drug repurposing in oncology--patient and health systems opportunities. Nat Rev Clin Oncol. 2015; 12(12):732-42. DOI: 10.1038/nrclinonc.2015.169. View

14.

Wu J, Waxman D . Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 T-cell responses and immune memory. Oncoimmunology. 2015; 4(4):e1005521. PMC: 4485826. DOI: 10.1080/2162402X.2015.1005521. View

15.

DAndrea A, Gritti I, Nicoli P, Giorgio M, Doni M, Conti A . The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas. Oncotarget. 2016; 7(45):72415-72430. PMC: 5341918. DOI: 10.18632/oncotarget.11719. View

16.

Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore M, Bertino J . Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Mol Ther. 2004; 10(3):574-84. DOI: 10.1016/j.ymthe.2004.06.115. View

17.

Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y . Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021; 39(12):1578-1593.e8. DOI: 10.1016/j.ccell.2021.09.010. View

18.

Carpen L, Falvo P, Orecchioni S, Mitola G, Hillje R, Mazzara S . A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. Cell Death Discov. 2022; 8(1):106. PMC: 8904804. DOI: 10.1038/s41420-022-00893-x. View

19.

Bocci G, Pelliccia S, Orlandi P, Caridi M, Banchi M, Musuraca G . Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J Clin Med. 2022; 11(23). PMC: 9739472. DOI: 10.3390/jcm11237162. View

20.

Wang D, Fang J, Wen S, Li Q, Wang J, Yang L . A comprehensive profile of TCF1 progenitor and TCF1 terminally exhausted PD-1CD8 T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy. Int J Oral Sci. 2022; 14(1):8. PMC: 8841504. DOI: 10.1038/s41368-022-00160-w. View